Filing Flows › Comparisons › DNA vs PLX
Ginkgo Bioworks Holdings vs Protalix BioTherapeutics: DNA and PLX compared
Ginkgo Bioworks Holdings is the larger company: $20.2M of revenue in its latest quarter (Q2 2026) against $19.9M for Protalix BioTherapeutics (Q2 2026). Protalix BioTherapeutics is growing faster (+27% against -48% a year earlier). Protalix BioTherapeutics is more profitable, with an operating margin of 23.5% against -290.5%.
Where the money goes: DNA and PLX
Ginkgo Bioworks Holdings (DNA) · Q2 2026
Ginkgo Bioworks Holdings, Q2 2026: revenue $20.2M (-48% year over year), operating margin -290.5%, net loss $46.7M, operating cash flow −$44.3M. The chart follows the revenue to costs, profit and cash.
Protalix BioTherapeutics (PLX) · Q2 2026
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
| Ginkgo Bioworks Holdings (DNA) | Protalix BioTherapeutics (PLX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $20.2M | $19.9M |
| Revenue growth, Y/Y | -48% | +27% |
| Operating margin | -290.5% | 23.5% |
| Net earnings | −$46.7M | $3.8M |
| Net margin | -231.7% | 19.0% |
| Operating cash flow | −$44.3M | −$10.4M |
Where the revenue comes from
Protalix BioTherapeutics
- GOODS: $19.8M (100%)
- LICENSE AND R&D SERVICES: $68K (0%)
Questions
Which is bigger, Ginkgo Bioworks Holdings or Protalix BioTherapeutics?
Ginkgo Bioworks Holdings is the larger company: $20.2M of revenue in its latest quarter (Q2 2026) against $19.9M for Protalix BioTherapeutics (Q2 2026).
Is Ginkgo Bioworks Holdings or Protalix BioTherapeutics growing faster?
Protalix BioTherapeutics is growing faster (+27% against -48% a year earlier).
Which is more profitable, Ginkgo Bioworks Holdings or Protalix BioTherapeutics?
Protalix BioTherapeutics is more profitable, with an operating margin of 23.5% against -290.5%.
More: Ginkgo Bioworks Holdings earnings · how Ginkgo Bioworks Holdings makes money · Protalix BioTherapeutics earnings · how Protalix BioTherapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.